Financial Gravity Asset Management, Inc. Aerie Pharmaceuticals Inc Transaction History

Financial Gravity Asset Management, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$9.12 - $14.49 $574 - $912	-63 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$12.0 - $16.13 $756 - $1,016	63 New	63 $1,000
Q4 2019 Feb 28, 2020	SELL	$17.72 - $25.1 $1,683 - $2,384	-95 Closed	0 $0
Q3 2019 Oct 15, 2019	BUY	$18.41 - $28.0 $717 - $1,092	39 Added 69.64%	95 $2,000
Q2 2019 Jul 26, 2019	SELL	$28.97 - $48.21 $753 - $1,253	-26 Reduced 31.71%	56 $2,000
Q1 2019 Apr 19, 2019	BUY	$36.32 - $49.25 $2,978 - $4,038	82 New	82 $4,000

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Financial Gravity Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Financial Gravity Asset Management, Inc. with notifications on news.